Physicians' Academy for Cardiovascular Education

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

10' education - May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Video navigation menu

  • A heterogeneity is seen in the benefit of empagliflozin in patients with HF 0:21
  • Proposed mechanism of benefit before the EMPA-REG Outcome trial 1:14
  • The surprising results have changed ideas on the mechanism of empagliflozin 2:51
  • Is the proposed mechanism just a diuretic effect or due to lowering blood pressure? 7:54
  • Patients with diabetes have higher HF risk 9:44
  • Emerging concept on the mechanism of benefit of SGLT2 inhibition. 10:40

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: